{"title":"Prediction of chemotherapy-mediated cardiotoxicity in patients with cancer by cardiac troponin I: A systematic review and meta-analysis.","authors":"Yang Liu, Huanglong Liu","doi":"10.1177/09246479241302586","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Cardiac damage is a significant risk of chemotherapy. Elevated circulating cardiac troponin I was suggested as a marker for early detection of cardiac damage.</p><p><strong>Objective: </strong>We aim to assess the predictive value of cardiac troponin I for chemotherapy-induced cardiotoxicity in cancer patients.</p><p><strong>Methods: </strong>We searched PubMed, Web of Science, Embase, and CNKI. Nine prospective studies involving 2033 cancer patients (pts) were included in the meta-analysis. Troponin I (TnI) levels in patients who underwent chemotherapy were categorized into cardiac troponin I (cTnI) positive and negative groups based on the cutoff concentrations described in the included studies. The cumulative effects of chemotherapy-induced cardiotoxicity between the cTnI-positive and cTnI-negative patients were represented as a summarized risk difference (RD) value with a 95% confidence interval. Subgroup analysis and sensitivity analysis were employed to address heterogeneities. Stata software (version 12.0) was utilized for the analysis.</p><p><strong>Results: </strong>cTnI-positive pts represented significant cardiotoxicity compared to cTnI-negative pts, as a decline in left ventricular ejection fraction (LVEF): RD = 0.279 [95% CI (0.248-0.311), <i>p</i> = 0.000, I<sup>2</sup> = 81.3%, 8 trials], heart failure (HF): RD = 0.117, [95% CI (0.090-0.144), <i>p</i> = 0.000, I<sup>2</sup> = 77.8%, 6 trials], arrhythmias: RD = 0.057 [95% CI (0.028-0.086), <i>p</i> = 0.000, I<sup>2</sup> = 0.0%, 3 trials], and cumulative events: RD = 0.318 [95% CI (0.272-0.364), <i>p</i> = 0.000, I<sup>2</sup> = 73.5%, 3 trials]. No statistically significant difference in cardiac death, acute pulmonary edema, and acute coronary syndromes between cTnI-positive pts and cTnI-negative pts was identified.</p><p><strong>Conclusions: </strong>An increase in circulating troponin I serve as a potential biomarker that reflecting the high risk of early cardiotoxicity in cancer patients who have undergone chemotherapy. The presence of intrinsic unadjusted confounding factors in the reports suggests the need for further study to address this question.</p>","PeriodicalId":45237,"journal":{"name":"INTERNATIONAL JOURNAL OF RISK & SAFETY IN MEDICINE","volume":" ","pages":"9246479241302586"},"PeriodicalIF":0.9000,"publicationDate":"2024-11-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"INTERNATIONAL JOURNAL OF RISK & SAFETY IN MEDICINE","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1177/09246479241302586","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Cardiac damage is a significant risk of chemotherapy. Elevated circulating cardiac troponin I was suggested as a marker for early detection of cardiac damage.
Objective: We aim to assess the predictive value of cardiac troponin I for chemotherapy-induced cardiotoxicity in cancer patients.
Methods: We searched PubMed, Web of Science, Embase, and CNKI. Nine prospective studies involving 2033 cancer patients (pts) were included in the meta-analysis. Troponin I (TnI) levels in patients who underwent chemotherapy were categorized into cardiac troponin I (cTnI) positive and negative groups based on the cutoff concentrations described in the included studies. The cumulative effects of chemotherapy-induced cardiotoxicity between the cTnI-positive and cTnI-negative patients were represented as a summarized risk difference (RD) value with a 95% confidence interval. Subgroup analysis and sensitivity analysis were employed to address heterogeneities. Stata software (version 12.0) was utilized for the analysis.
Results: cTnI-positive pts represented significant cardiotoxicity compared to cTnI-negative pts, as a decline in left ventricular ejection fraction (LVEF): RD = 0.279 [95% CI (0.248-0.311), p = 0.000, I2 = 81.3%, 8 trials], heart failure (HF): RD = 0.117, [95% CI (0.090-0.144), p = 0.000, I2 = 77.8%, 6 trials], arrhythmias: RD = 0.057 [95% CI (0.028-0.086), p = 0.000, I2 = 0.0%, 3 trials], and cumulative events: RD = 0.318 [95% CI (0.272-0.364), p = 0.000, I2 = 73.5%, 3 trials]. No statistically significant difference in cardiac death, acute pulmonary edema, and acute coronary syndromes between cTnI-positive pts and cTnI-negative pts was identified.
Conclusions: An increase in circulating troponin I serve as a potential biomarker that reflecting the high risk of early cardiotoxicity in cancer patients who have undergone chemotherapy. The presence of intrinsic unadjusted confounding factors in the reports suggests the need for further study to address this question.
期刊介绍：
The International Journal of Risk and Safety in Medicine is concerned with rendering the practice of medicine as safe as it can be; that involves promoting the highest possible quality of care, but also examining how those risks which are inevitable can be contained and managed. This is not exclusively a drugs journal. Recently it was decided to include in the subtitle of the journal three items to better indicate the scope of the journal, i.e. patient safety, pharmacovigilance and liability and the Editorial Board was adjusted accordingly. For each of these sections an Associate Editor was invited. We especially want to emphasize patient safety.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
